GLP-1 Weight Loss Medications · Bonita Springs, Fl
Semaglutide & Tirzepatide in Bonita Springs, FL
Physician-Supervised GLP-1 Weight Loss Medications Personalized, Lab-Based, and Monitored
Semaglutide (the active ingredient in Ozempic® and Wegovy®) and Tirzepatide (the active ingredient in Mounjaro® and Zepbound®) are FDA-approved GLP-1 receptor agonist medications that produce the most significant pharmacologic weight loss results in the history of obesity medicine — average losses of 15–21% of body weight in clinical trials. Dr. Katherine Ortiz at DNA Wellness and Longevity Institute in Bonita Springs prescribes both medications as part of physician-supervised, lab-evaluated weight management programs — not a telemedicine script with no follow-up.
Why patients choose us
Physician-Led
All GLP-1 programs prescribed and monitored by Dr. Katherine Ortiz, PA-C, Ph.D.
Complement, Not Replace
Candidacy confirmed with bloodwork not a questionnaire
SW Florida
Serving Bonita Springs, Naples, Estero & Fort Myers
How They Work
The Mechanism Behind GLP-1 Weight Loss Medications
GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating — it signals the pancreas to release insulin, slows gastric emptying so food stays in the stomach longer, and most importantly, acts on the hypothalamus to reduce appetite and increase satiety. GLP-1 receptor agonist medications mimic this hormone, producing these effects at sustained therapeutic concentrations that far exceed what natural GLP-1 achieves after a meal.
The result is a fundamental change in the relationship between hunger and eating. Patients on GLP-1 medications consistently describe reduced appetite, faster satiety with smaller portions, decreased food preoccupation, and reduced cravings — particularly for high-calorie and ultra-processed foods. The caloric deficit this produces is substantial without the willpower struggle of traditional restriction-based dieting, because the medication is suppressing the neurobiological hunger signals that make restriction so difficult to sustain.
Beyond appetite regulation, GLP-1 medications — particularly Tirzepatide — have demonstrated meaningful improvements in insulin sensitivity, fasting glucose, inflammatory markers, liver fat, and cardiovascular risk factors. The SURMOUNT-1 trial showed Tirzepatide reduced progression to diabetes by 94% in pre-diabetic patients. The SELECT trial showed Semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease. These are not incidental benefits — they reflect GLP-1's fundamental role in metabolic regulation.
Semaglutide vs. Tirzepatide
Understanding Your Options, Semaglutide vs. Tirzepatide
Semaglutide
Semaglutide (Wegovy® / Ozempic® / Compounded)
Semaglutide is a GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. It was FDA-approved for chronic weight management (Wegovy®) in 2021 and for type 2 diabetes management (Ozempic®) in 2017. Clinical trials have shown average body weight reduction of approximately 15% over 68 weeks when combined with lifestyle modification — representing a meaningful, sustained fat loss that significantly exceeds what diet and exercise alone typically achieve in a clinical setting.
Key clinical benefits:
Weight loss: Clinically meaningful average reduction of ~15% of body weight over 68 weeks in the STEP-1 trial; patients commonly report reduced appetite, earlier fullness, and decreased food preoccupation within the first 4 weeks of dose titration
Appetite and satiety: Acts centrally on hypothalamic GLP-1 receptors to reduce hunger signaling and increase satiety signals — the caloric deficit is achieved through biological appetite suppression, not willpower
Glycemic benefit: Enhances glucose-dependent insulin secretion and reduces glucagon, improving fasting glucose trends and post-meal glucose control — particularly relevant for pre-diabetic and diabetic patients
Cardiovascular benefit: The SELECT trial (17,604 patients, 3.3 years) demonstrated a 20% reduction in major adverse cardiovascular events (non-fatal MI, non-fatal stroke, cardiovascular death) in patients with obesity and established cardiovascular disease
Metabolic and inflammatory benefit: Reductions in inflammatory markers including C-reactive protein, consistent with lower obesity-related inflammatory burden
Emerging neurocognitive signal: Observational and target-trial-emulation studies suggest potential reduction in dementia and Alzheimer's-related outcomes, large prospective trials are ongoing and results are preliminary
Availability: FDA-approved brand Wegovy® is available at licensed pharmacies. Compounded Semaglutide was widely used during the Wegovy shortage; FDA shortage designations should be confirmed at consultation as availability changes. Dr. Ortiz prescribes based on the most current availability and appropriate clinical formulation.
Tirzepatide
Tirzepatide (Zepbound® / Mounjaro® / Compounded)
Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist — the first medication in its class — administered as a once-weekly subcutaneous injection. FDA-approved for chronic weight management as Zepbound® in 2023 and for type 2 diabetes as Mounjaro® in 2022. The dual agonism produces additive metabolic effects that make Tirzepatide the most effective pharmacologic weight loss agent currently available, with clinical trials showing average weight reductions of up to 20.9% over 72 weeks in the SURMOUNT-1 trial.
Key clinical benefits:
Weight loss: Average reduction of up to 20.9% of body weight over 72 weeks at the highest dose in SURMOUNT-1 — among the highest pharmacologic weight loss ever documented in a controlled trial; patients commonly report stronger appetite suppression than Semaglutide, with more pronounced reductions in cravings and food reward
Appetite, cravings, and meal control: The dual GLP-1/GIP mechanism produces stronger appetite suppression than GLP-1 alone — patients frequently report reduced snacking, better portion control, and decreased interest in high-calorie foods
Glycemic benefit: Improves glycemic control through both incretin mechanisms; particularly useful in insulin-resistant patients where the GIP component enhances insulin sensitivity in adipose tissue
Diabetes risk reduction: SURMOUNT-1 long-term data demonstrates a 94% relative risk reduction in progression from pre-diabetes to type 2 diabetes — one of the most significant diabetes prevention findings in pharmacologic history
Cardiovascular benefit: SURMOUNT-CVOT (ongoing) is evaluating cardiovascular outcomes; early data show favorable cardiometabolic effects consistent with Semaglutide's established SELECT trial findings
Metabolic and inflammatory burden: Clinical reduction in hs-CRP and improvements in obesity-related metabolic disease burden consistent with lower systemic inflammatory load
Availability: FDA-approved Zepbound® is available at licensed pharmacies. Compounded Tirzepatide availability varies with FDA guidance — current status confirmed at consultation. Dr. Ortiz monitors regulatory updates and prescribes the most appropriate formulation available.
Your Journey
What To Expect with Dr Ortiz
Step 01 — Candidacy Evaluation & Lab Work Your first appointment includes a comprehensive lab panel and clinical review. Dr. Ortiz evaluates your BMI, medical history, comorbidities, current medications, and the specific clinical question of which medication — Semaglutide or Tirzepatide — is most appropriate for your situation. Patients with type 2 diabetes or pre-diabetes, cardiovascular disease, significant insulin resistance, or prior partial response to Semaglutide may be better candidates for Tirzepatide's dual mechanism. Dr. Ortiz makes this determination at consultation based on your full clinical picture, not a preference checklist.
Step 02 — Dose Titration & Protocol Initiation Both medications are initiated at a low starting dose and titrated upward on a monthly schedule to allow the body to adapt and minimize gastrointestinal side effects — nausea, which is the most common side effect, is almost always dose-dependent and manageable with slow titration and dietary adjustment. Dr. Ortiz provides specific guidance on eating patterns, meal timing, and portion approach that significantly reduces side effect burden during the titration phase. Self-administered weekly subcutaneous injections are simple — Dr. Ortiz's team provides full injection training and ongoing support.
Step 03 — Monitoring, Optimization & Long-Term Management Follow-up appointments at 4–6 weeks assess your response, side effect profile, and dose appropriateness. Laboratory monitoring every 3–6 months tracks metabolic markers, liver enzymes, and the metabolic improvements the medication is producing. Dr. Ortiz integrates GLP-1 therapy with the hormonal and nutritional factors that affect its efficacy — thyroid status, sex hormones, and insulin sensitivity all influence medication response and are addressed concurrently where relevant. Long-term management discussions — including the evidence on weight regain after stopping and the clinical rationale for ongoing versus cyclical therapy — are part of every ongoing appointment.
Questions Answered
Frequently Asked Questions About Semaglutide & Tirzepatide
Q1: What is the difference between Semaglutide and Tirzepatide? Both are GLP-1 receptor agonists producing significant weight loss through appetite suppression and metabolic improvement — but Tirzepatide adds GIP receptor agonism, making it a dual-mechanism drug. In head-to-head and comparative analyses, Tirzepatide consistently produces greater average weight loss (up to 20.9% vs. ~15% for Semaglutide) and stronger appetite suppression. For most patients without contraindications, Tirzepatide is currently the more effective option where access and cost are equivalent. Semaglutide has a longer evidence base — particularly for cardiovascular outcomes (SELECT trial) — and may be preferred in specific clinical situations. Dr. Ortiz recommends the most appropriate option at consultation based on your clinical profile, comorbidities, and prior medication history.
Q2: Can I get Semaglutide or Tirzepatide at DNA Wellness if I don't have diabetes? Yes. Both Wegovy® (Semaglutide) and Zepbound® (Tirzepatide) are FDA-approved specifically for chronic weight management in non-diabetic adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity. Diabetes is not a requirement — these medications are approved and appropriate for obesity management as a primary indication. The Ozempic® and Mounjaro® brand names are approved for type 2 diabetes management specifically; the Wegovy® and Zepbound® formulations are the weight management versions, though the active ingredients are the same.
Q3: What are the side effects and how are they managed? The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite beyond the intended therapeutic effect. These are almost always dose-dependent — they occur most frequently during dose increases and improve as the body adapts. Slow titration (the standard approach Dr. Ortiz uses) significantly reduces their severity. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated during dose changes further reduces GI burden. Most patients who experience significant nausea during early titration find it largely resolves within 2–4 weeks at a stable dose. Rare but serious risks include pancreatitis, gallbladder disease (both more common in obesity itself), and — in patients with specific personal or family history — a theoretical risk of thyroid C-cell tumors (contraindicated in MEN2 or personal history of medullary thyroid cancer).
Q4: Will I regain the weight if I stop taking GLP-1 medications? This is an important question that Dr. Ortiz addresses at every weight management consultation. Clinical evidence clearly shows that weight regain occurs after stopping GLP-1 therapy — typically 2/3 of the weight lost returns within one year of discontinuation. This reflects the pharmacological nature of the intervention: the medication is suppressing appetite neurobiologically, and when removed, the appetite regulation returns to its prior state. This is not a character or willpower issue — it is the expected pharmacology. The clinical options are: long-term maintenance therapy (evidence supports continued efficacy and safety), cyclical therapy with active maintenance efforts during off-cycles, or transition to the lowest effective dose rather than complete discontinuation. Dr. Ortiz discusses the long-term strategy at every consultation so patients enter with accurate expectations.
Q5: Are Semaglutide and Tirzepatide available in Bonita Springs and Southwest Florida? Yes. DNA Wellness and Longevity Institute, located at 26800 S Tamiami Trail, Suite 380 in Bonita Springs, offers physician-supervised Semaglutide and Tirzepatide weight loss programs for patients throughout Bonita Springs, Naples, Estero, Fort Myers, and surrounding Southwest Florida communities. Call (239) 250-7930 to schedule your weight loss consultation with Dr. Ortiz.
Meet Dr. Katherine Ortiz
Dr. Katherine Ortiz is the founder of DNA Wellness and Longevity Institute in Bonita Springs, FL. She is a board-certified Physician Associate and holds a Ph.D. in Integrative Medicine from Quantum University, with fellowship training through the American Academy of Anti-Aging Medicine (A4M) and the University of South Florida in functional and regenerative medicine.
Her practice is built on a foundational belief: that the body has an extraordinary capacity to heal and self-regulate when given the right support. Dr. Ortiz investigates root causes — hormonal imbalances, nutritional deficiencies, genetic factors — and builds individualized protocols designed to restore function and optimize long-term health.
Every protocol at DNA Wellness is ordered, reviewed, and monitored directly by Dr. Ortiz.
